Pharmaceutical Preparations · DE · CIK 1933414
Developing medicines targeting diseases driven by dysregulated aldosterone, including hypertension and related conditions
Comparable business profile · signals at a glance
In the 90 days to Mar 30, 2026: 1 insider bought $8.8M · 3 sold $12.3M.
| Date | Insider | Action | Shares | Price | Value |
|---|---|---|---|---|---|
| Mar 30, 2026 | Shah Rajeev M.Director | Buy | 58,300 | $24.16 | $1.4M |
| Mar 27, 2026 | Shah Rajeev M.Director | Buy | 310,700 | $23.67 | $7.4M |
| Mar 17, 2026 | Rodman David MalcomChief Medical Officer | Sell | 417 | $25.65 | $11K |
| Mar 13, 2026 | Rodman David MalcomChief Medical Officer | Sell | 10,726 | $25.91 | $278K |
| Mar 13, 2026 | Rodman David MalcomChief Medical Officer | Sell | 3,079 | $27.37 | $84K |
| Mar 13, 2026 | Rodman David MalcomChief Medical Officer | Sell | 253 | $27.82 | $7K |
| Mar 12, 2026 | Rodman David MalcomChief Medical Officer | Sell | 6,348 | $27.37 | $174K |
| Mar 9, 2026 | Rodman David MalcomChief Medical Officer | Sell | 2,171 | $26.84 | $58K |
| Feb 17, 2026 | Rodman David MalcomChief Medical Officer | Sell | 417 | $27.59 | $12K |
| Feb 13, 2026 | Rodman David MalcomChief Medical Officer | Sell | 6,348 | $27.58 | $175K |
| Feb 13, 2026 | Rodman David MalcomChief Medical Officer | Sell | 4,166 | $27.33 | $114K |
| Feb 13, 2026 | Rodman David MalcomChief Medical Officer | Sell | 3,541 | $27.33 | $97K |
| Feb 12, 2026 | Rodman David MalcomChief Medical Officer | Sell | 5,828 | $28.94 | $169K |
| Feb 12, 2026 | Rodman David MalcomChief Medical Officer | Sell | 521 | $29.64 | $15K |
| Feb 9, 2026 | Rodman David MalcomChief Medical Officer | Sell | 2,171 | $30.21 | $66K |
| Jan 20, 2026 | Rodman David MalcomChief Medical Officer | Sell | 416 | $32.10 | $13K |
| Jan 14, 2026 | Rodman David MalcomChief Medical Officer | Sell | 11,367 | $32.61 | $371K |
| Jan 13, 2026 | Rodman David MalcomChief Medical Officer | Sell | 7,709 | $32.75 | $252K |
| Jan 12, 2026 | Levy Adam ScottCFO and Secretary | Sell | 10,758 | $32.14 | $346K |
| Jan 12, 2026 | Congleton JonChief Executive Officer | Sell | 9,119 | $32.21 | $294K |
Open-market buys & sells (Form 4, transaction codes P/S). Source: SEC structured insider data.